2024 JP Morgan Healthcare Conference
Q4 2023 UPDATE
YTD Q3 2023: Robust Organic Revenue Growth & EPS Growth
Healthy Preliminary Q4-23 Revenue Growth; Solid FY24 Outlook
✰ Revenue increased ~$288M, up +15.8%
Organic revenue growth +13.9%
BSI +14.0%
■
YTD Q3-23A Financials (year-over-year)
■
Acquisitions +2.0%, FX -0.1%
Non-GAAP EPS $1.50, up +12.8%
BEST +12.8%
BSI Geographic Revenue Mix YTD 3Q 2023
32%
2023 Bruker
33%
ROW ~4%
31%
BRUKER
Q4-23E Preliminary Estimates; FY24E Outlook
Q4 2023 Preliminary Estimates:
▪ Q4-23 revenue >$830M, with >12% organic growth
▪ Q4-23 reported revenue >$35M above consensus
▪ Q4-23 BSI bookings solid, including strong demand for NMR
▪ FY23 revenue >$2.94B, with >13% organic growth
▪
FY23 double-digit organic revenue & BSI bookings growth in
China
FY 2024 Preliminary Outlook:
▪
FY24 guidance in early February on Q4-23 earnings call
▪ For FY24, we expect solid, above-market organic
revenue growth and non-GAAP EPS growth
Innovation with Integrity |
January 8, 2024
1
15View entire presentation